Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 8/20 | 0.62 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612492 | 0.89 | PTK2 (0.56) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1612509 | 0.89 | PTK2 (0.57) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1612314 | 0.88 | EGFR (0.64) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL13803979 | 0.88 | PTK2 (0.55) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1611748 | 0.88 | PTK2 (0.55) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1613273 | 0.88 | PTK2 (0.55) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL12749425 | 0.86 | PTK2 (0.55) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1613518 | 0.86 | PTK2 (0.55) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1613520 | 0.86 | PTK2 (0.54) | PTK2EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1613386 | 0.84 | PTK2 (0.65) | PTK2EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885EGFR 2739/4885ERBB2 2203/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885EGFR 2739/4885ERBB2 2203/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885EGFR 2739/4885ERBB2 2203/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PTK2 833/4885EGFR 2739/4885ERBB2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.